Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

The analysts said the paused trial in CSU, a medical term for hives, is the most important of the three studies ... now ...

The company states: “Incyte (INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria ... Phase 2 study evaluating MRGPRX4 in cholestatic ...

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Report Ocean has published a new report on the Pruritus Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

Biopharma Technology Co. Ltd. has led to the identification of Mas-related G-protein coupled receptor member X4 (MRGPRX4; SNSR5; SNSR6) antagonists reported to be useful for the treatment of anemia, ...

A pruritus-free day was defined as the absence ... prior to unblinding with the WHO-ART dictionary. All resources with URTICARIA in their preferred term were selected. All medical resources ...